- Report
- February 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- April 2025
- 150 Pages
Global
From €4430EUR$4,850USD£3,788GBP
- Report
- May 2024
- 185 Pages
Global
From €4110EUR$4,500USD£3,515GBP
- Report
- September 2023
- 236 Pages
Global
From €5434EUR$5,950USD£4,647GBP
- Report
- February 2022
- 180 Pages
Global
From €4064EUR$4,450USD£3,476GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1370EUR$1,500USD£1,172GBP
- Report
- February 2024
- 72 Pages
Global
From €3500EUR$4,105USD£3,098GBP
Ertapenem is an antibiotic used to treat a variety of bacterial infections. It belongs to a class of antibiotics known as carbapenems, which are broad-spectrum antibiotics used to treat serious infections caused by multiple drug-resistant bacteria. Ertapenem is typically used to treat infections of the urinary tract, skin, and soft tissue, as well as intra-abdominal infections. It is also used to treat bacterial meningitis. Ertapenem is generally well-tolerated and has a low risk of adverse effects.
Ertapenem is available in both generic and brand-name formulations. It is typically administered intravenously or intramuscularly, and is available in various dosage forms, including tablets, capsules, and injections. Ertapenem is often used in combination with other antibiotics to treat serious infections.
Ertapenem is a widely used antibiotic, and is available from many pharmaceutical companies, including Merck, Pfizer, and Teva Pharmaceuticals. It is also available from generic drug manufacturers such as Mylan and Sandoz. Show Less Read more